Cargando…

Analysis of von Willebrand Disease in the “Heart of Europe”

Background  von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives  Complete laboratory analysis of VWD as an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Vangenechten, Inge, Smejkal, Petr, Zavrelova, Jiri, Zapletal, Ondrej, Wild, Alexander, Michiels, Jan Jacques, Berneman, Zwi, Blatny, Jan, Batorova, Angelika, Prigancova, Tatiana, Penka, Miroslav, Gadisseur, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581583/
https://www.ncbi.nlm.nih.gov/pubmed/36299619
http://dx.doi.org/10.1055/s-0042-1757635
_version_ 1784812657201643520
author Vangenechten, Inge
Smejkal, Petr
Zavrelova, Jiri
Zapletal, Ondrej
Wild, Alexander
Michiels, Jan Jacques
Berneman, Zwi
Blatny, Jan
Batorova, Angelika
Prigancova, Tatiana
Penka, Miroslav
Gadisseur, Alain
author_facet Vangenechten, Inge
Smejkal, Petr
Zavrelova, Jiri
Zapletal, Ondrej
Wild, Alexander
Michiels, Jan Jacques
Berneman, Zwi
Blatny, Jan
Batorova, Angelika
Prigancova, Tatiana
Penka, Miroslav
Gadisseur, Alain
author_sort Vangenechten, Inge
collection PubMed
description Background  von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives  Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name “Heart of Europe,” in order to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods  In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. Results  A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1–3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. Conclusion  This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations.
format Online
Article
Text
id pubmed-9581583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-95815832022-10-25 Analysis of von Willebrand Disease in the “Heart of Europe” Vangenechten, Inge Smejkal, Petr Zavrelova, Jiri Zapletal, Ondrej Wild, Alexander Michiels, Jan Jacques Berneman, Zwi Blatny, Jan Batorova, Angelika Prigancova, Tatiana Penka, Miroslav Gadisseur, Alain TH Open Background  von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives  Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name “Heart of Europe,” in order to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods  In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. Results  A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1–3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. Conclusion  This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations. Georg Thieme Verlag KG 2022-10-19 /pmc/articles/PMC9581583/ /pubmed/36299619 http://dx.doi.org/10.1055/s-0042-1757635 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Vangenechten, Inge
Smejkal, Petr
Zavrelova, Jiri
Zapletal, Ondrej
Wild, Alexander
Michiels, Jan Jacques
Berneman, Zwi
Blatny, Jan
Batorova, Angelika
Prigancova, Tatiana
Penka, Miroslav
Gadisseur, Alain
Analysis of von Willebrand Disease in the “Heart of Europe”
title Analysis of von Willebrand Disease in the “Heart of Europe”
title_full Analysis of von Willebrand Disease in the “Heart of Europe”
title_fullStr Analysis of von Willebrand Disease in the “Heart of Europe”
title_full_unstemmed Analysis of von Willebrand Disease in the “Heart of Europe”
title_short Analysis of von Willebrand Disease in the “Heart of Europe”
title_sort analysis of von willebrand disease in the “heart of europe”
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581583/
https://www.ncbi.nlm.nih.gov/pubmed/36299619
http://dx.doi.org/10.1055/s-0042-1757635
work_keys_str_mv AT vangenechteninge analysisofvonwillebranddiseaseintheheartofeurope
AT smejkalpetr analysisofvonwillebranddiseaseintheheartofeurope
AT zavrelovajiri analysisofvonwillebranddiseaseintheheartofeurope
AT zapletalondrej analysisofvonwillebranddiseaseintheheartofeurope
AT wildalexander analysisofvonwillebranddiseaseintheheartofeurope
AT michielsjanjacques analysisofvonwillebranddiseaseintheheartofeurope
AT bernemanzwi analysisofvonwillebranddiseaseintheheartofeurope
AT blatnyjan analysisofvonwillebranddiseaseintheheartofeurope
AT batorovaangelika analysisofvonwillebranddiseaseintheheartofeurope
AT prigancovatatiana analysisofvonwillebranddiseaseintheheartofeurope
AT penkamiroslav analysisofvonwillebranddiseaseintheheartofeurope
AT gadisseuralain analysisofvonwillebranddiseaseintheheartofeurope